Varubi Dosage
Generic name: ROLAPITANT HYDROCHLORIDE 90mg
Dosage form: tablet
Drug class: NK1 receptor antagonists
Medically reviewed by Drugs.com. Last updated on Aug 9, 2024.
The recommended dosage of VARUBI in adults in combination with a 5-HT3 receptor antagonist and dexamethasone for the prevention of nausea and vomiting with emetogenic cancer chemotherapy is shown in Table 1. There is no drug interaction between rolapitant and dexamethasone, so no dosage adjustment for dexamethasone is required. Administer a dexamethasone dose of 20 mg on Day 1.
Administer VARUBI prior to the initiation of each chemotherapy cycle, but at no less than 2 week intervals.
Administer VARUBI without regards to meals.
Day 1 | Day 2 | Day 3 | Day 4 | |
Prevention of Nausea and Vomiting Associated with Cisplatin-Based Highly Emetogenic Cancer Chemotherapy | ||||
VARUBI | 180 mg as a single dose orally within 2 hours prior to initiation of chemotherapy | None | ||
Dexamethasone | 20 mg; 30 min prior to initiation of chemotherapy | 8 mg twice daily | 8 mg twice daily | 8 mg twice daily |
5-HT3 receptor antagonist | See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information. | None | ||
Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemotherapy and Combinations of Anthracycline and Cyclophosphamide | ||||
VARUBI | 180 mg as a single dose orally within 2 hours prior to initiation of chemotherapy | None | ||
Dexamethasone | 20 mg; 30 min prior to initiation of chemotherapy | None | ||
5-HT3 receptor antagonist | See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information. | See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information. |
Frequently asked questions
More about Varubi (rolapitant)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: NK1 receptor antagonists
- En español
Patient resources
- Varubi drug information
- Varubi (Rolapitant Intravenous) (Advanced Reading)
- Varubi (Rolapitant Oral) (Advanced Reading)
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.